[EQ] Ensuring value for money in health care: The role of health technology assessment in the European Union

Ensuring value for money in health care: The role of health technology assessment in the European Union

Corinna Sorenson is a Research Officer at LSE Health, London School of Economics and Political Science, and a Ph.D. candidate in the Department of Social Policy.
Michael Drummond is Professor of Health Economics at the University of York, Centre for Health Economics.
Panos Kanavos is Senior Lecturer in International Health Policy in the Department of Social Policy and Merck Fellow in Pharmaceutical Economics at LSE Health, London School of Economics and Political Science.

World Health Organization on behalf of the European Observatory on Health Systems and Policies - 2008

Available online as PDF file [179p.] at: http://www.euro.who.int/document/E91271.pdf

 

“….This book provides a detailed review of the role of health technology assessment (HTA) in the European Union. It examines related methodological and process issues in the prioritization and financing of modern health care, and presents extensive case studies on the situation in Sweden, the Netherlands, Finland, France, Germany and the United Kingdom.

A number of issues are examined and there is a particular emphasis on the responsibility and membership of HTA bodies, assessment procedures and methods, the application of HTA evidence to decision-making, and the dissemination and implementation of findings. The book aims to highlight ways in which the HTA process in Europe could be improved by examining key challenges and identifying potential opportunities to support value and innovation in health care. …”

 

The European Observatory on Health Systems and Policies is a partnership between the World Health Organization Regional Office for Europe, the Governments of Belgium, Finland, Greece, Norway, Slovenia, Spain and Sweden, the Veneto Region of Italy, the European Investment Bank, the Open Society Institute, the World Bank, the London School of Economics and Political Science and the London School of Hygiene & Tropical Medicine.

 

Content:
Executive summary

1 Project overview, objectives and methods

2 Background on innovation and HTA

3 HTA and decision-making in Europe

4 Conclusions

Appendices: Select country case studies

Appendix 1: Sweden

Appendix 2: The Netherlands

Appendix 3: Finland

Appendix 4: France

Appendix 5: Germany

Appendix 6: United Kingdom

References

 

 

 *      *      *     *

This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues.  [DD/ KMS Area]

“Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members”.
------------------------------------------------------------------------------------

PAHO/WHO Website: http://www.paho.org/

EQUITY List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html

 

    IMPORTANT: This transmission is for use by the intended recipient and it may contain privileged, proprietary or confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please notify us immediately by email to infosec@paho.org, and please dispose of and delete this transmission. Thank you.  

[EQ] A Policy Road Map for Canad a=?iso-2022-jp?Q?=1B$B!G=1B(Bs?= Health Research, Innovation & Commercialization Enterprise

Our Paths to Prosperity…A Policy Road Map for Canada's Health Research, Innovation and Commercialization Enterprise

 

The Association of Canadian Academic Healthcare Organizations (ACAHO), the national voice of Teaching Hospitals, Regional Health Authorities and their Research Institutes (known as Research Hospitals) – April 2008

 

Available online at: http://www.acaho.org/docs/pdf_2008_april_sandt_response_en.pdf

"…..The Brief is builds on the Science and Technology Strategy "Mobilizing Science and Technology to Canada's Advantage" that was released by the federal government in 2007. ACAHO has identified 10 recommendations for the health research community and governments to consider. These recommendations focus on the country's health research, innovation and commercialization enterprise.

 

……Considered as essential building blocks, these principles should be reflected in any future policy framework that is focused on the country's health research, innovation and commercialization enterprise:

 

-    Excellence-Based: The starting point for all health research – is that we must focus on the principle of excellence. Embedded in this principle is the critical role that the peer-review process does play in identifying leading-edge research projects that merit support, and produce world-class results.

 

 

-    Collaboration and Partnership: There are many interlocking pieces associated with the health research, innovation and commercialization enterprise that need to be functioning at an optimal level if we, collectively, are to harness their full benefits. With this in mind, it is critical that all components of the research spectrum (e.g., federal and provincial governments, and their respective funding agencies; the private sector, members of ACAHO, Universities and Health Charities) work collaboratively, in partnership so that the sum that flows from research, innovation and commercialization is significantly greater than its component parts.

 

 

-    Accountability: Understanding that members of ACAHO reflect some of the most important public institutions in the country, it is a necessary and sufficient condition that they be accountable and transparent for the manner in which they set their strategic priorities, invest in the health research, innovation and commercialization enterprise, and to the extent possible, identify anticipated outcomes and impacts.

 

 

-   Value-for-Money: If we are to continue to grow Canada's health research, innovation and commercialization enterprise, we must continually strive for new methods in which we can effectively capture and communicate the different ways in which new discoveries, as well as products and services contribute to the advancement of Canadian society and the larger global community.

 

 

-   Integration: It is essential that the health research, innovation and commercialization enterprise, from early-stage, discovery-based research, to knowledge creation and translation, to the process of development, commercialization and market access, be considered within an over-arching integrated framework (i.e., health research eco-system). To maximize our overall "return-on-investment", we must ensure that all policy levers, wherever possible, are mutually reinforcing, and moving in the same direction.

 

 

-          Values-Driven: Any discussion about the research, innovation and commercialization enterprise must be consistent with the core values that Canadians hold. The view of ACAHO is that health research, innovation and commercialization builds on the publicly-funded platform of Medicare, and looks to improve the health of Canadians, the cost-effective manner in which health services are delivered, and how we can contribute to sustained economic prosperity. In short, it is about better health and health care, and a vision for nation-building. …."

 

Eureka! World First Discoveries and Other Major Medical Breakthrough in ACAHO Member Institutions
http://www.acaho.org/docs/pdf_2008_mar_eureka_en.pdf

 

Eureka! focuses on the essential role that Canada's Research Hospitals play in creating the knowledge that comes from investments in health research. As a result, many world first discoveries have revolutionized the way in which cost-effective quality health services are delivered to Canadians, and the rest of the world. Some of the discoveries include:

● The discovery of insulin in 1922

● The first artificial kidney machine in 1948

● The first use of the "cobalt bomb" to treat cancer in 1951

● Discovered the gene defect responsible for Duchenne Muscular Dystrophy in 1987

● Discovered the gene that causes cystic fibrosis in 1989

● The first physical map of the human genome in 1995

● Sequencing of the SARS genome in 2003

● Performed first hospital-to-hospital telerobotic assisted surgery more than 400 kms away in 2003

● Identified nine factors that can predict heart attacks in 2003

● Treating prostate cancer using 3-D image guided radiation therapy in 2005

*      *      *     *

This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues.  [DD/ KMS Area]

"Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members".
------------------------------------------------------------------------------------

PAHO/WHO Website: http://www.paho.org/

EQUITY List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html

 

 

    IMPORTANT: This transmission is for use by the intended recipient and it may contain privileged, proprietary or confidential information. If you are not the intended recipient or a person responsible for delivering this transmission to the intended recipient, you may not disclose, copy or distribute this transmission or take any action in reliance on it. If you received this transmission in error, please notify us immediately by email to infosec@paho.org, and please dispose of and delete this transmission. Thank you.